Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9082975 | 1.00 | ALOX5 (0.44) | ALOX5PPARGKDM4ELMNAALDH1A1 | |
| SCHEMBL13851482 | 1.00 | ALOX5 (0.44) | ALOX5PPARGKDM4ELMNAALDH1A1 | |
| SCHEMBL16160330 | 0.87 | CYP1A2 (0.44) | KDM4ELMNAALDH1A1CYP1A2 | |
| SCHEMBL9562978 | 0.86 | ALDH1A1 (0.42) | ALOX5PPARGKDM4ELMNAALDH1A1 | |
| SCHEMBL9401416 | 0.86 | CYP1A2 (0.42) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL9082706 | 0.84 | KDM4E (0.39) | ALOX5PPARGKDM4ELMNAALDH1A1 | |
| SCHEMBL9563038 | 0.84 | ALDH1A1 (0.40) | ALOX5PPARGKDM4EALDH1A1PTGES | |
| SCHEMBL9563040 | 0.84 | ALDH1A1 (0.35) | ALOX5PPARGKDM4EALDH1A1CYP1A2 | |
| SCHEMBL9083929 | 0.83 | KDM4E (0.38) | ALOX5PPARGKDM4ELMNAALDH1A1 | |
| SCHEMBL9230745 | 0.83 | ALOX5 (0.36) | ALOX5PPARGKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095565-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140301975-A1 | Methods for Treating Blood Disorders | PHOENICIA BIOSCIENCES INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301975-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | ALOX5 2153/4885PPARG 4009/4885KDM4E 3792/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | ALOX5 2153/4885PPARG 4009/4885KDM4E 3792/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | ALOX5 1313/4885PPARG 194/4885KDM4E 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.